Augmented Inducible Nitric Oxide Synthase Expression and Increased NO Production Reduce Sepsis-induced Lung Injury and Mortality in Myeloperoxidase-null Mice
Overview
Molecular Biology
Physiology
Pulmonary Medicine
Authors
Affiliations
The myeloperoxidase (MPO)-hydrogen peroxide-halide system is an efficient oxygen-dependent antimicrobial component of polymorphonuclear leukocyte (PMN)-mediated host defense. However, MPO deficiency results in few clinical consequences indicating the activation of compensatory mechanisms. Here, we determined possible mechanisms protecting the host using MPO(-/-) mice challenged with live gram-negative bacterium Escherichia coli. We observed that MPO(-/-) mice unexpectedly had improved survival compared with wild-type (WT) mice within 5-12 h after intraperitoneal E. coli challenge. Lungs of MPO(-/-) mice also demonstrated lower bacterial colonization and markedly attenuated increases in microvascular permeability and edema formation after E. coli challenge compared with WT. However, PMN sequestration in lungs of both groups was similar. Basal inducible nitric oxide synthase (iNOS) expression was significantly elevated in lungs and PMNs of MPO(-/-) mice, and NO production was increased two- to sixfold compared with WT. Nitrotyrosine levels doubled in lungs of WT mice within 1 h after E. coli challenge but did not change in MPO(-/-) mice. Inhibition of iNOS in MPO(-/-) mice significantly increased lung edema and reduced their survival after E. coli challenge, but iNOS inhibitor had the opposite effect in WT mice. Thus augmented iNOS expression and NO production in MPO(-/-) mice compensate for the lack of HOCl-mediated bacterial killing, and the absence of MPO-derived oxidants mitigates E. coli sepsis-induced lung inflammation and injury.
Morandini L, Avery D, Angeles B, Winston P, Martin R, Donahue H Acta Biomater. 2023; 166:670-684.
PMID: 37187302 PMC: 10330750. DOI: 10.1016/j.actbio.2023.05.016.
Myeloperoxidase: Regulation of Neutrophil Function and Target for Therapy.
Rizo-Tellez S, Sekheri M, Filep J Antioxidants (Basel). 2022; 11(11).
PMID: 36421487 PMC: 9687284. DOI: 10.3390/antiox11112302.
Johnson J, Meneses-Salas E, Ramadass M, Monfregola J, Rahman F, Carvalho Gontijo R Nat Commun. 2022; 13(1):5529.
PMID: 36130971 PMC: 9492659. DOI: 10.1038/s41467-022-33230-y.
Targeting Neutrophils for Promoting the Resolution of Inflammation.
Filep J Front Immunol. 2022; 13:866747.
PMID: 35371088 PMC: 8966391. DOI: 10.3389/fimmu.2022.866747.
Myeloperoxidase: a new target for the treatment of stroke?.
Wang Y, Lu Y, Huang X, Lao Y, Zhang L, Yang J Neural Regen Res. 2022; 17(8):1711-1716.
PMID: 35017418 PMC: 8820716. DOI: 10.4103/1673-5374.332130.